Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: a phase II trial

Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: a phase II trial

Background Immune checkpoint inhibitors (ICIs) to date have demonstrated limited activity in advanced ovarian cancer (OC). Folate receptor alpha (FRα) is overexpressed in the majority of OCs and presents an attractive target for a combination immunotherapy to potentially overcome resistance to ICI i...

Full description

Saved in:
Bibliographic Details
Main Authors: Dmitriy Zamarin, Taha Merghoub, Yanyun Li, Travis J Hollmann, Jason A Konner, Qin Zhou, Carol Aghajanian, Roisin E O’Cearbhaill, Aliya Holland, Rachel N Grisham, Keith L Knutson, Sven Walderich, Alexia E Iasonos, Jean M Torrisi, Lewis F Chesebrough, Autumn S Mcdonnell, Jacqueline M Gallagher, Courtney L Erskine
Format: Article
Language:English
Published: BMJ Publishing Group 2020-05-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/8/1/e000829.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://jitc.bmj.com/content/8/1/e000829.full

Similar Items